bluebird bio (BLUE) News Today $4.97 0.00 (0.00%) As of 06/2/2025 Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLUE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Analysts Set bluebird bio, Inc. (NASDAQ:BLUE) PT at $44.601 hour ago | americanbankingnews.comPetri Dish: ProFound’s Novartis deal worth $750M, Dyne secures debtJuly 3, 2025 | bizjournals.combluebird bio Strengthens Leadership Team With New AppointmentsJuly 1, 2025 | finance.yahoo.comEssential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive DirectorJune 25, 2025 | finance.yahoo.comCarlyle, SK Capital close deal for bluebird bio, injecting capital for commercial expansionJune 2, 2025 | bizjournals.combluebird bio Announces Completion of Acquisition by Carlyle and SK CapitalJune 2, 2025 | businesswire.combluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK CapitalJune 1, 2025 | finance.yahoo.combluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK CapitalMay 30, 2025 | insidermonkey.comCarlyle Expects bluebird Deal to be Concluded SoonMay 30, 2025 | baystreet.cabluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK CapitalMay 30, 2025 | msn.comGene Therapy Death Worsens Picture for an Already Troubled FieldMay 27, 2025 | msn.combluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK CapitalMay 27, 2025 | businesswire.comHigh Noon For bluebirdMay 25, 2025 | seekingalpha.comBluebird bio soars on amended deal with Carlyle, SK CapitalMay 15, 2025 | msn.comBluebird Bio Shares Soar After Carlyle, SK Capital Offer AmendedMay 14, 2025 | marketwatch.comBluebird Bio Stock Soars On Higher Upfront Payment Under Amended Merger Deal: Retail Gets More BullishMay 14, 2025 | msn.combluebird bio shares soar after amended buyout offer from Carlyle, SK CapitalMay 14, 2025 | proactiveinvestors.comCarlyle, SK Capital Partners and bluebird bio Amend Merger AgreementMay 14, 2025 | tmcnet.comBluebird bio receives higher upfront offer from PE firms Carlyle, SK CapitalMay 14, 2025 | reuters.combluebird bio nears acquisition by Carlyle and SK CapitalMay 7, 2025 | uk.investing.comNew gene therapy considered cure for Sickle Cell Disease being administered at St. Louis Children’s HospitalMay 5, 2025 | msn.comCarlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bioMay 5, 2025 | finance.yahoo.combluebird bio Inc.April 24, 2025 | wsj.comBluebird Bio Says Ayrmid Failed To Submit Formal Offer, Confirms Carlyle, SK Deal; Stock FellApril 18, 2025 | nasdaq.comBluebird bio reaffirms Carlyle deal as Ayrmid misses deadlineApril 17, 2025 | finance.yahoo.comBluebird bio shares fall amid acquisition woesApril 16, 2025 | au.investing.comBluebird reports Ayrmid did not submit binding proposal to acquire the companyApril 16, 2025 | markets.businessinsider.combluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagementApril 16, 2025 | finance.yahoo.combluebird bio's board opts for sale to U.S. investment firmsApril 16, 2025 | bizjournals.combluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.comApril 14, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $231,000 Stock Holdings in bluebird bio, Inc. (NASDAQ:BLUE)April 3, 2025 | marketbeat.comBluebird Bio Receives $4.50 Per Share Acquisition Proposal From AyrmidApril 2, 2025 | nasdaq.comXcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell diseaseApril 2, 2025 | finance.yahoo.comBluebird Bio price target lowered to $8 from $40 at BarclaysMarch 31, 2025 | markets.businessinsider.comBluebird Bio (BLUE) Gets a Buy from BarclaysMarch 31, 2025 | markets.businessinsider.comBluebird Bio Shares Rise After Non-Binding Offer From AyrmidMarch 31, 2025 | marketwatch.comGene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock JumpsMarch 31, 2025 | benzinga.comBluebird Bio confirms receipt non-binding proposal from AyrmidMarch 29, 2025 | markets.businessinsider.comBluebird bio reports another acquisition offer for $45M upfrontMarch 28, 2025 | bizjournals.comBluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- UpdateMarch 28, 2025 | marketwatch.comBluebird bio receives non-binding bid for up to $110.5 millionMarch 28, 2025 | reuters.combluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from AyrmidMarch 28, 2025 | businesswire.comGene therapy loses luster as investors eye quicker returns from weight-loss drugsMarch 21, 2025 | msn.comIn the Thymus We Trust: ProTcell Therapy & the Future of Allogeneic ImmunotherapyMarch 18, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUEMarch 17, 2025 | prnewswire.comMan Cured Of Sickle Cell Disease In New York Thanks To New Gene TherapyMarch 15, 2025 | forbes.comBristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M DealMarch 12, 2025 | msn.comBristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy PioneerMarch 12, 2025 | seekingalpha.comBristol Myers acquires cell therapy partner 2seventy bio for about $286 millionMarch 11, 2025 | msn.com2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300MMarch 11, 2025 | finance.yahoo.com Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Media Mentions By Week BLUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLUE News Sentiment▼0.480.57▲Average Medical News Sentiment BLUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLUE Articles This Week▼13▲BLUE Articles Average Week Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bright Minds Biosciences News Today Y-mAbs Therapeutics News Today CytomX Therapeutics News Today Eledon Pharmaceuticals News Today Organigram Global News Today GENFIT News Today 4D Molecular Therapeutics News Today Cybin News Today Alumis News Today Tiziana Life Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLUE) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLUE Stock Alerts